上下肢康复机器人检验常见问题的讨论

随着我国医疗器械技术的发展,上下肢康复机器人作为一种新型的医疗器械出现在大众面前,很大程度上替代了传统的康复训练,提高了康复训练的效率。但是上下肢康复机器人的出现也伴随着一些问题,文章结合上下肢康复机器人的一些标准及广东省医疗器械质量监督检验所近年来对上下肢康复机器人的检测情况进行探讨,并提出一些问题和建议,以期能够规范上下肢康复机器人的市场和提高上下肢康复机器人的产品质量。     

全身振动训练在脑瘫儿童下肢康复训练中的应用进展

全身振动训练是一种神经肌肉训练方法,由振动平台产生机械刺激通过脚底向全身传递,进而引起患者生理功能的改变。近期全身振动训练在脑瘫儿童康复中的应用日益广泛,研究发现全身振动训练对脑瘫儿童康复起着积极作用,本文主要就全身振动训练对脑瘫儿童下肢功能的影响进行阐述。     

COVID-19 and Infant Hospitalizations for Seasonal Respiratory Virus Infections,New Zealand, 2020

In March 2020, a national elimination strategy for coronavirus disease was introduced in New Zealand. Since then, hospitalizations for lower respiratory tract infection among infants <2 years of age and cases of respiratory syncytial or influenza virus infection have dramatically decreased. These findings indicate additional benefits of coronavirus disease control strategies.     

益气活血药对低氧性肺动脉高压大鼠神经肽Y、降钙素基因相关肽的影响

目的：探讨由黄芪、川芎组方的益气活血药对低氧性肺动脉高压大鼠神经肽Y（NPY）、 降钙素基因相关肽（CGRP）的影响。方法：采用常压低氧21天复制大鼠肺动脉高压模型,应用放射免疫技术测定大鼠血浆、肺组织中NPY、CGRP的含量变化。结果：益气活血药可降低肺动脉压,改善心功能及血液流变学。益气活血药中剂量组血浆及肺组织中NPY含量与缺氧组比较明显降低;而CGRP含量较缺氧组有所回升,肺组织中CGRP含量与缺氧组比较则趋于下降。结论：益气活血药可防止低氧性肺动脉高压的形成,也提示益气活血药的降压作用可能通过影响NPY、CGRP的含量来调节肺血管舒缩,从而降低肺动脉压。     

益气止血药对脾不统血证模型动物前列腺素的作用

采用复合因素的脾不统血证大鼠模型 ,以 6 酮 前列腺素F1α(6 酮 PGF1α)和血栓素B2(TXB2 )作为观测指标 ,对益气止血药对脾不统血证模型大鼠血浆和子宫前列腺素的影响进行了研究。结果 :大剂量组益气止血药能降低脾不统血证模型血浆和子宫的 6 酮 PGF1α及子宫 6 酮 PGF1α/TXB2 比值。说明 6 酮 PGF1α及 6 酮 PGF1α/TXB2 比值升高可能是脾不统血证的重要机理之一。     

急性下肢缺血性疾病的介入治疗

目的 探讨应用介入方法治疗急性下肢缺血性疾病的临床效果及安全性。方法 21例患按基础病因不同分为两组,对无患肢慢性缺血史给予单纯动脉内灌注尿激酶,对存在有患肢慢性缺血史在给予适当尿激酶30万u后,应用超滑导丝通过闭塞段,顺导丝送入球囊导管行PTA术。结果 第1组8例,获得成功,1例于术后第3天死于急性左心功能不全;第2组9例获得成功,3例在发病5日后行截肢术。结论 (1)多种介入方法联合治疗急性下肢缺血临床效果可靠。(2)基础性病因是决定介入方法选择的首要因素。     

15种理气中药体外对人血小板聚集的影响

目的观察15种理气中药对体外肾上腺素诱导的人血小板聚集的影响.方法试管内人血小板加中药孵育前后,比浊法测定血小板聚集.结果11种理气药具有抗血小板聚集作用(P＜0.05～0.001),其中枳实的抑制作用较阳性对照阿司匹林明显(P＜0.01),青皮、陈皮与阿司匹林无差异(P＜0.05).柿蒂、甘松、檀香、沉香对血小板聚集无明显作用(P＞0.05).结论多数理气药(11/15)在体外具有抗人血小板聚集作用,枳实、青皮、陈皮3种作用强于或与阿司匹林相当.     

一氧化氮对犬下食管括约肌压力的作用

目的 :应用苄基二甲基十四烷氯化铵 (benzyldim ethyltetradecyl amm onium chloride,BAC)建立犬下食管括约肌(L ES)无神经动物模型 ,研究一氧化氮 (NO)对 L ES压力的作用。方法 :将 BAC环周注入犬 L ES,对照组注入等量生理盐水 ,均于注射前及注射后 6周测定 L ES压力 ;并观察 L -精氨酸、D -精氨酸、硝普钠及一氧化氮合酶 (NOS)抑制剂 N-硝基 - L -精氨酸 (L - NNA)对 L ES压力的影响 ;此外还测定了两组犬 L ES中 NO含量和 NOS活性。结果 :BAC处理组 L ES压力 [(4 2 .43±4.19) m m Hg,1m m Hg=0 .133 k Pa]显著高于对照组 [(2 2 .71± 5 .19) mm Hg]。 L -精氨酸可使对照组 L ES压力降低 ;L - NNA使其增高 ,但对 BAC处理组 L ES压力均无影响。硝普钠可降低两组犬 L ES压力。对照组 L ES中 NO为 (6 .0 5 8± 2 .0 6 7)μm ol/g,NOS为 (1.45 8± 0 .146 ) U /mg;而 BAC处理组 NO为 (1.797± 0 .873)μmol/g,NOS为 (0 .46 3± 0 .0 39) U /m g,均较对照组显著降低 (P<0 .0 1)。 结论 :BAC可使犬 L ES压力增高 ,其机制可能与 L ES局部 NO减少有关。     

Nonalcoholic fatty liver disease and risk of prostatic diseases: Roles of insulin resistance

Nonalcoholic fatty liver disease (NAFLD), the liver component of metabolic syndrome, is considered to be associated with high risk of prostatic diseases but a systematic review has not been conducted. Under a comprehensive review of the eligible clinical studies, a potential positive association between NAFLD and benign prostatic hyperplasia/prostate cancer (BPH/PCa) has been postulated. Insulin resistance and metabolic aberrations are considered to be the potential mechanism for such association. However, the relationship between NAFLD and other prostatic diseases, that is, prostatic inflammation and lower urinary tract symptoms, seems vague due to limited relevant studies in the literatures. The present review highlights that clinicians should be conscious of the detrimental effect of NAFLD on the development of BPH and PCa.     

Outcomes and complications of naftopidil versus tamsulosin for elderly men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review and meta-analysis

We conducted a systematic review and meta-analysis to assess the outcomes and complications of naftopidil in treating elderly men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and compared them with those administered with tamsulosin. A literature review was performed to identify the available randomised controlled trials concerning the comparison between naftopidil and tamsulosin for men with LUTS/BPH. We searched the following databases: the Cochrane Library Database, PubMed, Embase and Web of Science. Eleven publications involving 1,114 men (557 in the naf group and 557 in the tam group) were pooled in our analysis. We found no significant differences in the total IPSS, IPSS storage score, IPSS voiding score, quality of life index, peak urinary flow rate, average flow rate and post-void residual volumes. We assessed cardiovascular and sexual adverse events, acute urinary retention, surgical intervention, withdrawals due to any reason and withdrawals due to adverse events. The incidence of adverse events was similar among patients in naf and tam groups. In conclusion, naftopidil shared comparable efficacy and similar incidence of adverse events with tamsulosin and appears to be a promising agent for and alternative to tam. However, more prospective trials with high quality and long-term treatment duration are needed to verify this observation.